Myelosuppression example sentences

"Myelosuppression" Example Sentences

1. Myelosuppression is a significant side effect of many chemotherapy regimens.
2. The patient experienced severe myelosuppression following the high-dose chemotherapy.
3. Monitoring blood counts is crucial for detecting early signs of myelosuppression.
4. Treatment for myelosuppression may include growth factors.
5. Myelosuppression, a common adverse effect, necessitates careful monitoring.
6. The severity of myelosuppression varied among patients in the trial.
7. He developed myelosuppression, requiring a delay in treatment.
8. Managing myelosuppression is a key aspect of supportive oncology care.
9. Preventing myelosuppression is a primary goal of some treatment strategies.
10. This new drug shows promise in reducing myelosuppression associated with chemotherapy.
11. Researchers are investigating new methods to mitigate myelosuppression.
12. The patient's low blood counts indicated significant myelosuppression.
13. A reduction in myelosuppression was observed after the dose reduction.
14. Careful monitoring for myelosuppression is essential throughout treatment.
15. The onset of myelosuppression typically occurs within a few weeks of treatment.
16. Severe myelosuppression can lead to serious infections.
17. Myelosuppression-related complications are a major concern.
18. Supportive care interventions are vital in managing myelosuppression.
19. The study aimed to evaluate the incidence of myelosuppression in different treatment groups.
20. Due to myelosuppression, the patient required a blood transfusion.
21. Risk factors for myelosuppression include age and pre-existing conditions.
22. Myelosuppression is a dose-limiting toxicity of this drug.
23. Early detection of myelosuppression allows for timely intervention.
24. Patients with severe myelosuppression may require hospitalization.
25. The degree of myelosuppression can be measured by various blood tests.
26. Prophylactic measures may help reduce the risk of myelosuppression.
27. We observed a correlation between dose intensity and myelosuppression.
28. Managing the side effects of myelosuppression is challenging.
29. This case highlights the importance of recognizing and managing myelosuppression.
30. The patient's recovery from myelosuppression was slow but steady.
31. Long-term effects of myelosuppression are still under investigation.
32. Myelosuppression significantly impacts quality of life.
33. Understanding the mechanisms of myelosuppression is crucial for developing new therapies.
34. The incidence of myelosuppression was higher in the experimental group.
35. Further research is needed to improve the management of myelosuppression.
36. Myelosuppression can affect all blood cell lineages.
37. Treatment-related myelosuppression is a major obstacle to effective cancer therapy.
38. The severity of myelosuppression necessitates dose adjustments.
39. Patients experiencing myelosuppression require close monitoring and support.
40. Myelosuppression is a common complication of radiation therapy.
41. The study found no significant difference in myelosuppression between the two arms.
42. Myelosuppression, though serious, is often reversible.
43. Genetic factors may influence susceptibility to myelosuppression.
44. Reducing myelosuppression improves treatment tolerance.
45. Prolonged myelosuppression can increase the risk of infections.
46. The use of growth factors helped minimize myelosuppression in this case.
47. This article reviews the current strategies for managing myelosuppression.
48. Careful consideration of myelosuppression risk is vital in treatment planning.
49. The clinical significance of myelosuppression cannot be overstated.
50. Future research should focus on novel approaches to preventing myelosuppression.